Home / Resource Library / Ibrutinib Plus Rituximab Shows Efficacy in Indolent Mantle Cell Lymphoma

Ibrutinib Plus Rituximab Shows Efficacy in Indolent Mantle Cell Lymphoma

ICML 2021: Results of a study examining ibrutinib combined with rituximab for first line treatment of indolent mantle cell lymphoma.